What is Avalo Therapeutics's change in AP?

Avalo Therapeutics (AVTX) reported change in AP of $219K in Q1 2026.

How has Avalo Therapeutics's change in AP changed year-over-year?

Avalo Therapeutics's change in AP decreased by 45.0% year-over-year, from $398K to $219K.

What is the long-term trend for Avalo Therapeutics's change in AP?

Over 2 years (2023 to 2025), Avalo Therapeutics's change in AP has grown at a -75.7% compound annual growth rate (CAGR), from -$2.47M to -$146K.

What does change in AP mean?

Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.

Avalo Therapeutics AVTX Change in AP

Change in AP at other companies

Eli LillyLLY

$2.55B+290%

AbbVieABBV

-$1.59B-129%

XencorXNCR

-$2.87M-405%

AbCellera Biologics Inc.ABCL

-$9.41M-176%

AnaptysBio, Inc.ANAB

-$17.82M+25.9%

Absci CorporationABSI

-$2.04M+6.5%

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,800%

Enterprise value$929.6M-1,353%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's change in AP?: Avalo Therapeutics (AVTX) reported change in AP of $219K in Q1 2026.
How has Avalo Therapeutics's change in AP changed year-over-year?: Avalo Therapeutics's change in AP decreased by 45.0% year-over-year, from $398K to $219K.
What is the long-term trend for Avalo Therapeutics's change in AP?: Over 2 years (2023 to 2025), Avalo Therapeutics's change in AP has grown at a -75.7% compound annual growth rate (CAGR), from -$2.47M to -$146K.
What does change in AP mean?: Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.